BEACON CRC Trial Results: New Therapy for Advanced Bowel Cancer
BRAF Mutation and Patient Prognosis
Recent findings from the BEACON CRC trial introduce a promising triple therapy drug combination for treating advanced bowel cancer. Approximately 15% of patients with advanced bowel cancer exhibit a mutation in the BRAF gene, which is associated with a significantly poor prognosis. Those who do not respond to initial standard chemotherapy often face an average overall survival of only four to six months. This underscores the urgent need for targeted treatments for BRAF-mutated advanced bowel cancer.
Trial Overview and Methodology
The BEACON CRC trial, conducted by researchers in the United States, aimed to assess the impact of a three-drug combination on overall survival rates in patients with BRAF-mutated advanced bowel cancer. The findings were published in the *Annals of Oncology*. This multi-centre, randomized trial evaluated the efficacy and safety of encorafenib, binimetinib, and cetuximab in patients who had previously failed standard therapies. The results were compared to a control group receiving conventional combination treatments for advanced bowel cancer.
Patient Outcomes and Efficacy
The study involved 665 patients with BRAF-mutant advanced bowel cancer who had failed initial chemotherapy. Those receiving the triple therapy had a median overall survival of nine months, in contrast to 5.4 months for the control group. Additionally, the objective response rates were significantly higher in the triple therapy group at 26%, compared to just 2% in the standard therapy group. Notably, the side effects were consistent with the expected profiles of the drugs used, and the triple therapy was better tolerated than standard treatments.
Implications for Future Treatment
The substantial improvement in overall survival rates indicated by the study suggests a hopeful advancement in treating advanced bowel cancer, particularly as the combination therapy does not involve chemotherapy agents. This aspect spares patients from the adverse effects typically associated with chemotherapy.
Importance of BRAF Mutation Testing
Given the trial’s promising results, researchers emphasize the necessity of BRAF mutation testing for all bowel cancer patients. The targeted triple therapy is recommended specifically for those who have previously failed initial standard chemotherapy. Furthermore, a clinical trial named ANCHOR-CRC is currently examining the potential of this triple therapy as a first-line treatment for patients with BRAF mutations.
References
Kopetz, S., Grothey, A., Cutsem, E. V., Yaeger, R., Wasan, H., Yoshino, T., . . . Tabernero, J. (2019). LBA-006BEACON CRC: A randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. *Annals of Oncology*, 30(Supplement_4). doi:10.1093/annonc/mdz183.004
Targeted Therapy Combination Improves Survival in Patients with Advanced Bowel Cancer [ESMO World GI Press Release]. (2019, July 06). Retrieved from https://www.esmo.org/Press-Office/Press-Releases/ESMO-World-Congress-Gastrointestinal-Cancer-Encorafenib-Binimetinib-Cetuximab-Colorectal-BRAFV600E-Beacon-Kopetz